Nasdaq:US$8.66 (-0.50) | HKEX:HK$13.80 (+0.28) | AIM:£1.59 (-0.08)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 3 Jun 2014

ASCO 2014: First-in-Human Phase I study of a selective c-Met inhibitor AZD6094 (savolitinib) in patients with advanced solid tumors